ClinicalTrials.gg
RecruitingNCT07073248NIMBLEUpdated Nov 21, 2025

Effects of Intermitted Theta Burst Stimulation (iTBS) on Motor Recovery of Upper Extremity in Chronic Stroke Patients

An interventional study of Intermittent Theta Burst Stimulation and Sham Intermittent Theta Burst Stimulation in Stroke, Hemiplegia and Hemiparesis After Stroke, sponsored by Danderyd Hospital. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Danderyd Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Stroke by Danderyd Hospital — 2 open to participants now, 2 under way, none of them phase 3. Stroke · Danderyd Hospital.

Planned enrollment
2nd of 10
48 · median 22
Started
2025
with 1 other
No phase
10 of 12
2 open now
Registered
10th of 12
by date

Among the 12 studies in Stroke by Danderyd Hospital, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 with no phase, and was the 10th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

2 of the 12 studies in Stroke by Danderyd Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Stroke by Danderyd Hospital, or all of them as a file.
02

Study summary

This study aims to evaluate the effects and clinical feasibility of non-invasive brain stimulation protocols, specifically intermittent Theta Burst Stimulation, as part of rehabilitation interventions for motor recovery of upper extremity in the chronic phase after stroke.

It also seeks to explore the underlying mechanisms by investigating changes of functional and structural brain networks.

Read the detailed description

In this randomized controlled trial (RCT) group A will receive iTBS while group B will receive sham iTBS. Both groups will directly after the intervention receive 45 minutes of conventional physical therapy 3 times per week for 5 weeks, a total of 15 interventions by a blinded physiotherapist. For the iTBS intervention a Magstim Rapid² stimulator will be used also equipped with a Cadwell Sierra Summit EMG system [for motor evoked potential (MEP) measurements] and an ANT Visor2™ neuronavigation system [for navigated transcranial magnetic stimulation (TMS) interventions]. The iTBS parameters that will be used are: 600 pulses under 190 seconds at 80 % of Active Motor Threshold (AMT). The ipsilesional motor cortex will be targeted. The participants and clinical assessors will be blinded to the intervention.

All the patients will undergo advanced neuroimaging examinations before and after the intervention period. The exams will be then compared to identify neuroplastic changes in brain circuits.

03

Conditions studied

  • Stroke
  • Hemiplegia
  • Hemiparesis After Stroke
  • Hand Functionality
  • Chronic Stroke Patients

Keywords

  • stroke
  • iTBS
  • TMS
  • Motor cortex
  • chronic stroke patients
  • hand dexterity
  • Hemiparesis
  • Transcrania Magnetic Stimulation
  • intermittent Theta Burst Stimulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 18
  • Chronic stroke (>6 months)
  • Residual hemiparesis FM-UE>17

Exclusion criteria

Exclusion Criteria:

  • Metal implants
  • Epilepsy/seizures
  • Pregnancy
  • Claustrophobia (related to MRIs exams)
  • Severe cognitive impairment
  • Untreated or unstable depression/anxiety
  • Other disabilities prohibiting intensive physical training
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Ipsilesional motor cortex iTBS and conventional rehabilitation

    The experimental group will receive intermittent theta burst stimulation on the ipsilesional motor cortex followed by 45 minutes of conventional rehabilitation interventions involving the upper extremity led or instructed by a physiotherapist.

    Device: Intermittent Theta Burst Stimulation

  • Sham comparator
    Ipsilesional motor cortex sham-iTBS and conventional rehabilitation

    The placebo group will receive sham intermittent theta burst stimulation on the ipsilesional motor cortex followed by 45 minutes of conventional rehabilitation interventions involving the lower extremity led or instructed by a physiotherapist.

    Device: Sham Intermittent Theta Burst Stimulation

Interventions

  • DeviceIntermittent Theta Burst Stimulation

    iTBS protocol: 600 pulses at 80% of AMT for 190 sec on the ipsilesional motor cortex, targeted with the support of a neuronavigational system, 15 sessions over a period of 5 weeks

    Also known as: iTBS, TMS

  • DeviceSham Intermittent Theta Burst Stimulation

    It is identical to its active version, replicates operational sounds, and delivers a very shallow magnetic field to mimic the sensation of magnetic stimulation

06

What researchers measure

Primary outcomes

  1. Fugl-Meyer Assessment - Upper Extremity

    used to quantify recovery of sensorimotor function in the upper extremity after a stroke. It is a 63 item test scored on a 3-level ordinal scale. The score ranges from 0 to 126 points. A higher score indicates recovery of sensorimotor function.

    Time frame: At baseline, after completion of the 5 week intervention to assess change as well at 12 weeks follow up.

Secondary outcomes

  1. Modified Ashworth Scale (MAS)

    Assesses spasticity on a 6 point scale/muscle (0p no impairment, 5p max impairment/muscle)

    Time frame: At baseline, after completion of the 5 week intervention to assess change as well at 12 weeks follow up.

  2. Neuroflexor

    Medical technology device. Assesses spasticity by identifying the neural, viscous and elastic components during passive movement using a biomechanical algorithm (presented in Newton)

    Time frame: At baseline, after completion of the 5 week intervention to assess change as well at 12 weeks follow up.

  3. Box and Block Test (BBT)

    measures unilateral gross manual dexterity. The score is based on the number of blocks transferred from one compartment to the other compartment in 60 seconds. Higher scores indicate better manual dexterity.

    Time frame: At baseline, after completion of the 5 week intervention to assess change as well at 12 weeks follow up.

  4. Action Research Arm Test (ARAT)

    assesses upper extremity activity capacity in people with stroke. It is a 19-item test scored on a 4-level ordinal scale (0-3). The score ranges from 0 to 57. Higher scores indicate better performance of the upper extremity.

    Time frame: At baseline, after completion of the 5 week intervention to assess change as well at 12 weeks follow up.

  5. Dextrain Manipulandum™

    allows measurement of flexion-extension finger movements. Force sensors are incorporated in the ergonomically designed tool allowing precision measurement of finger movements. The tool is coupled with specific exercises for evaluation of key components of manual dexterity.

    Time frame: At baseline, after completion of the 5 week intervention to assess change as well at 12 weeks follow up.

  6. Hand-held Dynamometer/Grip Strength

    A quantitative and objective measure of isometric muscular strength of the hand and forearm. This instrument is scored using force production: kilograms or pounds. Maximum grip is the mean of three trials.

    Time frame: At baseline, after completion of the 5 week intervention to assess change as well at 12 weeks follow up.

  7. Purdue Pegboard Test (PPT)

    is a test of fingertip dexterity and gross movement of the hand, fingers and arm in patients with impairments of the upper extremity resulting from neurological and musculoskeletal conditions. Number of correctly placed pinns within a time frame are counted and a higher scores indicate better dexterity.

    Time frame: At baseline, after completion of the 5 week intervention to assess change as well at 12 weeks follow up.

  8. Visuomotor force tracking

    Subjects perform a visually guided, isometric precision grip ramp-and-hold force-tracking task by holding a manipulandum. The standardized visuomotor ramp-and-hold task is performed by following the target force with a cursor on a screen as precisely as possible.

    Time frame: At baseline and after completion of the 5 week intervention and at the 12 weeks follow up, to assess changes

  9. Montreal Cognitive Assessment (MoCA)

    Assesses mental function (0p max impairment summed up to 30p no detected impairment)

    Time frame: At baseline, after completion of the 5 week intervention to assess change as well at 12 weeks follow up.

  10. Canadian Occupational Performance Measure

    Capture the participant´s perception of performance in everyday living and will be used to set goals for the intervention.

    Time frame: At baseline, after completion of the 5 week intervention to assess change as well at 12 weeks follow up.

  11. Stroke Impact Scale (SIS)

    is a self-report questionnaire that evaluates disability and health-related quality of life after stroke. It has 8 domains: strength, hand function, mobility, physical and instrumental activities of daily living (ADL and IADL), memory and thinking, communication, emotion, and social participation. It uses a 5-point Likert scale to assess the difficulty of performing various tasks within each domain. Higher scores indicate better outcome.

    Time frame: At baseline and after completion of the 5 week intervention and at the 12 weeks follow up, to assess changes

  12. Motor Evoked Potentials (MEPs)

    electrical signals recorded from neural tissue or muscle following activation of central motor pathways. MEPs assess the integrity of descending motor pathways.

    Time frame: At baseline, after completion of the 5 week intervention to assess change as well at 12 weeks follow up.

  13. Resting state functional MRI (rs-fMRI)

    a method aimed at examining intrinsic networks in the brain while no task is performed (rest); this is to estimate correlations between brain regions.

    Time frame: At baseline and after completion of the 5 week intervention to assess changes.

  14. Diffusion Tension Imaging (DTI)

    a method aimed at mapping structural correlations between brain regions.

    Time frame: At baseline and after completion of the 5 week intervention to assess changes.

Other outcomes

  1. National Institutes of Health Stroke Scale (NIHSS)

    quantifies stroke severity based on weighted evaluation findings. The total NIHSS score ranges from 0 to 42, with higher scores indicating more severe strokes, categorized as follows: minor stroke (1-4), moderate stroke (5-15), moderate to severe stroke (16-20), and severe stroke (21-42).

    Time frame: At baseline

  2. Barthel Index (BI)

    measures a person's ability to complete activities of daily living (ADL). Scores range from 0 to 100, categorized as follows: Total dependence (0-20), Severe dependence (21-60), Moderate dependence (61-90), Slight dependence (91-99), and Independence (100).

    Time frame: At baseline.

  3. Theoretical Framework of Acceptability questionnaire

    to assess the acceptability of healthcare interventions, based on the developed Theoretical Framework of Acceptability (TFA). It uses a 5-point Likert scale to assess acceptability of the intervention. Higher scores indicate higher acceptability.

    Time frame: After completion of the 5 week intervention to assess acceptability.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lemon RN. Descending pathways in motor control. Annu Rev Neurosci. 2008;31:195-218. doi: 10.1146/annurev.neuro.31.060407.125547. PubMed 18558853 ↗
  • Zhang JJ, Bai Z, Fong KNK. Priming Intermittent Theta Burst Stimulation for Hemiparetic Upper Limb After Stroke: A Randomized Controlled Trial. Stroke. 2022 Jul;53(7):2171-2181. doi: 10.1161/STROKEAHA.121.037870. Epub 2022 Mar 23. PubMed 35317611 ↗
  • Zhang JJ, Sui Y, Sack AT, Bai Z, Kwong PWH, Sanchez Vidana DI, Xiong L, Fong KNK. Theta burst stimulation for enhancing upper extremity motor functions after stroke: a systematic review of clinical and mechanistic evidence. Rev Neurosci. 2024 Apr 29;35(6):679-695. doi: 10.1515/revneuro-2024-0030. Print 2024 Aug 27. PubMed 38671584 ↗
  • Jiang T, Wei X, Wang M, Xu J, Xia N, Lu M. Theta burst stimulation: what role does it play in stroke rehabilitation? A systematic review of the existing evidence. BMC Neurol. 2024 Feb 1;24(1):52. doi: 10.1186/s12883-023-03492-0. PubMed 38297193 ↗
  • van Lieshout ECC, van der Worp HB, Visser-Meily JMA, Dijkhuizen RM. Timing of Repetitive Transcranial Magnetic Stimulation Onset for Upper Limb Function After Stroke: A Systematic Review and Meta-Analysis. Front Neurol. 2019 Dec 3;10:1269. doi: 10.3389/fneur.2019.01269. eCollection 2019. PubMed 31849827 ↗
  • Lefaucheur JP, Andre-Obadia N, Antal A, Ayache SS, Baeken C, Benninger DH, Cantello RM, Cincotta M, de Carvalho M, De Ridder D, Devanne H, Di Lazzaro V, Filipovic SR, Hummel FC, Jaaskelainen SK, Kimiskidis VK, Koch G, Langguth B, Nyffeler T, Oliviero A, Padberg F, Poulet E, Rossi S, Rossini PM, Rothwell JC, Schonfeldt-Lecuona C, Siebner HR, Slotema CW, Stagg CJ, Valls-Sole J, Ziemann U, Paulus W, Garcia-Larrea L. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol. 2014 Nov;125(11):2150-2206. doi: 10.1016/j.clinph.2014.05.021. Epub 2014 Jun 5. PubMed 25034472 ↗
  • Christiansen MG, Senko AW, Anikeeva P. Magnetic Strategies for Nervous System Control. Annu Rev Neurosci. 2019 Jul 8;42:271-293. doi: 10.1146/annurev-neuro-070918-050241. Epub 2019 Apr 2. PubMed 30939100 ↗
  • Fan H, Song Y, Cen X, Yu P, Biro I, Gu Y. The Effect of Repetitive Transcranial Magnetic Stimulation on Lower-Limb Motor Ability in Stroke Patients: A Systematic Review. Front Hum Neurosci. 2021 Sep 1;15:620573. doi: 10.3389/fnhum.2021.620573. eCollection 2021. PubMed 34539362 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Dec 2030, 61 months later.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 61 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Jul 18, 2025
StartEst.
Nov 2025
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07073248
Lead sponsor
Danderyd Hospital
Responsible party
Susanne Palmcrantz (PhD, Associate Professor, Reg Physiotherapist, Danderyd Hospital) — Principal investigator
First posted
Jul 18, 2025
Start date
Nov 2025 (estimated)
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 21, 2025

Study contacts

Susanne Palmcrantz, PhD, Associate Professor
Contact
susanne.palmcrantz@ki.se
004681235000
Susanne Palmcrantz, PhD, Associate Professor
principal investigator · Dep of Clinical Sciences, Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion